Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Capital Employed (2018 - 2025)

Historic Return on Capital Employed for Protagonist Therapeutics (PTGX) over the last 8 years, with Q3 2025 value amounting to 0.03%.

  • Protagonist Therapeutics' Return on Capital Employed fell 2400.0% to 0.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.03%, marking a year-over-year decrease of 2400.0%. This contributed to the annual value of 0.5% for FY2024, which is 8300.0% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Return on Capital Employed is 0.03%, which was down 2400.0% from 0.03% recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Return on Capital Employed peaked at 0.4% during Q4 2024, and registered a low of 0.66% during Q1 2023.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.29% (2023), whereas its average is 0.2%.
  • As far as peak fluctuations go, Protagonist Therapeutics' Return on Capital Employed skyrocketed by 9900bps in 2024, and later plummeted by -2900bps in 2025.
  • Over the past 5 years, Protagonist Therapeutics' Return on Capital Employed (Quarter) stood at 0.4% in 2021, then plummeted by -41bps to 0.56% in 2022, then skyrocketed by 48bps to 0.29% in 2023, then soared by 239bps to 0.4% in 2024, then plummeted by -93bps to 0.03% in 2025.
  • Its Return on Capital Employed stands at 0.03% for Q3 2025, versus 0.03% for Q2 2025 and 0.04% for Q1 2025.